NCT03176524View on ClinicalTrials.gov

A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

September 4, 2017

Study Completion Date

September 4, 2017

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

BioChaperone® glucagon formulation 1

Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg

DRUG

BioChaperone® glucagon formulation 2

Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg

DRUG

GlucaGen® HypoKit®

Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Adocia
All Listed Sponsors
lead

Adocia

INDUSTRY